News | September 10, 2007

Vaccine Based on Listeria Aims to Stop Breast Cancer

September 11, 2007 — Researchers continue to search for a treatment to eradicate cancer, one of mankind's greatest afflictions and although a "cure" remains elusive, a vaccine to treat and prevent it may just be on the horizon.

Yvonne Paterson, Ph.D., a scientist who is also a breast cancer survivor, and her team of researchers appear to have taken a giant step forward by developing a series of cancer-fighting vaccines that appear to be able to stop and even reverse cancer growth.

Central to this discovery is the microbe Listeria monocytogenes, a bacterium found in milk, cheese and other dairy products. This common microorganism apparently aids in fighting cancer by activating many simultaneous mechanisms of immunity, including the body's own killer cells creating a strong immune response to the presence of cancer cells.

In scientific studies published in peer reviewed journals this year, Dr. Paterson, Professor of Microbiology at the University of Pennsylvania and scientific director at Advaxis, presented evidence of the cancer-fighting properties of live modified Listeria cancer vaccines. These vaccines successfully eradicated several types of rapidly growing cancers in mice.

When Listeria is introduced in the body, it has an extremely powerful effect, essentially, the Listeria in the vaccine harness the power of the immune system against the microbe, then proceed to direct it to successfully attack cancer cells. The vaccines teach the immune system to mount a specialized, targeted response that is lethal to cancer cells.

Advaxis is now preparing for clinical trials of Lovaxin B, their cancer-fighting vaccine for the treatment of breast cancer. The goal is to treat women who have pre-existing breast cancer with Lovaxin B by invoking an immune system response that will prevent the reoccurrence of the cancer.

For more information: www.advaxis.com

Related Content

MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016
Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a...
BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer
News | Interventional Radiology | February 09, 2016
BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first...
Overlay Init